Literature DB >> 21575891

Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report.

Adam Doyle1, Geoff Forbes, Nick Kontorinis.   

Abstract

We present the case of a 60-year-old Caucasian male with Crohn's disease treated with infliximab. Within 14 weeks of treatment induction, an asymptomatic acute hepatitis was detected. Elevated autoantibodies and liver biopsy findings supported the diagnosis of autoimmune hepatitis. No competing aetiologies were present. The hepatitis completely responded to infliximab cessation and administration of corticosteroids. This case is the most compelling to date of an infliximab-induced autoimmune hepatitis. Although the role of liver enzyme monitoring is unclear, an awareness of this adverse effect is important, given the potential for a rapid and complete response to specific treatment.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575891     DOI: 10.1016/j.crohns.2010.12.007

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  15 in total

Review 1.  Autoimmune hepatitis: a review.

Authors:  Andrea A Gossard; Keith D Lindor
Journal:  J Gastroenterol       Date:  2012-04-17       Impact factor: 7.527

Review 2.  Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.

Authors:  A Grasland; R Sterpu; S Boussoukaya; I Mahe
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

3.  Severe cholestasis due to adalimumab in a Crohn's disease patient.

Authors:  Edward Kim; Brian Bressler; David F Schaeffer; Eric M Yoshida
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  Infliximab-related hepatitis: a case study and literature review.

Authors:  Francisco Colina; Aída Molero; Begoña Casís; Pilar Martínez-Montiel
Journal:  Dig Dis Sci       Date:  2013-05-05       Impact factor: 3.199

Review 5.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

6.  Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.

Authors:  Susana Rodrigues; Susana Lopes; Fernando Magro; Hélder Cardoso; Ana Maria Horta e Vale; Margarida Marques; Eva Mariz; Miguel Bernardes; Joanne Lopes; Fátima Carneiro; Guilherme Macedo
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 7.  Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.

Authors:  Roberta Elisa Rossi; Ioanna Parisi; Edward John Despott; Andrew Kenneth Burroughs; James O'Beirne; Dario Conte; Mark Ian Hamilton; Charles Daniel Murray
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 8.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

9.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

Review 10.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.